biodel inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports biodel inc  product pipeline review   biodel inc  product pipeline review   wgr  february  global  pages global markets direct description table of content sample report enquiry before buy related reports biodel inc  product pipeline review  summaryglobal markets direct’s ‘biodel inc  product pipeline review  ’ provides an overview of the biodel inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of biodel inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of biodel inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of biodel inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the biodel inc’s pipeline productsreasons to buy evaluate biodel inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of biodel inc in its therapy areas of focus identify new drug targets and therapeutic classes in the biodel inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of biodel inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of biodel inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of biodel inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures biodel inc snapshot biodel inc overview key information key facts biodel inc  research and development overview key therapeutic areas biodel inc  pipeline review pipeline products by stage of development pipeline products  monotherapy biodel inc  pipeline products glance biodel inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities biodel inc  early stage pipeline products preclinical productscombination treatment modalities biodel inc  drug profiles biod product description mechanism of action rd progress biod product description mechanism of action rd progress biod product description mechanism of action rd progress biod product description mechanism of action rd progress biod product description mechanism of action rd progress glucagon product description mechanism of action rd progress viatab product description mechanism of action rd progress biod product description mechanism of action rd progress teriparatide product description mechanism of action rd progress viacal product description mechanism of action rd progress biodel inc  pipeline analysis biodel inc  pipeline products by target biodel inc  pipeline products by route of administration biodel inc  pipeline products by molecule type biodel inc  pipeline products by mechanism of action biodel inc  recent pipeline updates biodel inc  dormant projects biodel inc  discontinued pipeline products discontinued pipeline product profiles biod biod linjeta biodel inc  company statement biodel inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesbiodel inc key information biodel inc key facts biodel inc  pipeline by indication  biodel inc  pipeline by stage of development  biodel inc  monotherapy products in pipeline  biodel inc  phase ii  biodel inc  phase i  biodel inc  preclinical  biodel inc  pipeline by target  biodel inc  pipeline by route of administration  biodel inc  pipeline by molecule type  biodel inc  pipeline products by mechanism of action  biodel inc  recent pipeline updates  biodel inc  dormant developmental projects biodel inc  discontinued pipeline products  biodel inc other locations biodel inc subsidiaries list of figuresbiodel inc  pipeline by top  indication  biodel inc  pipeline by stage of development  biodel inc  monotherapy products in pipeline  biodel inc  pipeline by top  target  biodel inc  pipeline by top  route of administration  biodel inc  pipeline by top  molecule type  biodel inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send biodel inc  product pipeline review    rnr market research advanced search     salesrnrmarketresearchcom search market research reports ﻿ market research assistance salesrnrmarketresearchcom on the web related markets orthopedic therapeuticscardiovascular therapeuticsurology therapeuticskidneyrenal therapeuticspulmonary therapeuticsneurology therapeuticscancer therapeuticsrespiratory therapeuticsarthritis therapeuticsmens health therapeutics related market reportsbiodel inc  product pipeline review   home  life sciences  pharmaceuticals  therapeutics  diabetes therapeutics  report detail biodel inc  product pipeline review   publisher name  global markets direct date feb no of pages  price single user license us  corporate user license us  report descriptiontable of contentnews  blogother reportsour offerings global markets directs biodel inc  product pipeline review   provides an overview of the biodel incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of biodel incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of biodel inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of biodel incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the biodel incs pipeline products reasons to buy evaluate biodel incs strategic position with total access to detailed information on its product pipeline assess the growth potential of biodel inc in its therapy areas of focus identify new drug targets and therapeutic classes in the biodel incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of biodel inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of biodel inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of biodel inc and identify potential opportunities in those areas avoid intellectual property rights related issues biodel inc  product pipeline review   table of contents table of contents  list of tables  list of figures  biodel inc snapshot  biodel inc overview  key information  key facts  biodel inc  research and development overview  key therapeutic areas  biodel inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  biodel inc  pipeline products glance  biodel inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  biodel inc  early stage pipeline products  preclinical productscombination treatment modalities  biodel inc  drug profiles  biod  product description  mechanism of action  rd progress  biod  product description  mechanism of action  rd progress  biod  product description  mechanism of action  rd progress  biod  product description  mechanism of action  rd progress  biod  product description  mechanism of action  rd progress  glucagon  product description  mechanism of action  rd progress  viatab  product description  mechanism of action  rd progress  biod  product description  mechanism of action  rd progress  teriparatide  product description  mechanism of action  rd progress  viacal  product description  mechanism of action  rd progress  biodel inc  pipeline analysis  biodel inc  pipeline products by target  biodel inc  pipeline products by route of administration  biodel inc  pipeline products by molecule type  biodel inc  pipeline products by mechanism of action  biodel inc  recent pipeline updates  biodel inc  dormant projects  biodel inc  discontinued pipeline products  discontinued pipeline product profiles  biod  biod  linjeta  biodel inc  company statement  biodel inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables biodel inc key information  biodel inc key facts  biodel inc  pipeline by indication   biodel inc  pipeline by stage of development   biodel inc  monotherapy products in pipeline   biodel inc  phase ii   biodel inc  phase i   biodel inc  preclinical   biodel inc  pipeline by target   biodel inc  pipeline by route of administration   biodel inc  pipeline by molecule type   biodel inc  pipeline products by mechanism of action   biodel inc  recent pipeline updates   biodel inc  dormant developmental projects  biodel inc  discontinued pipeline products   biodel inc other locations  biodel inc subsidiaries  list of figures biodel inc  pipeline by top  indication   biodel inc  pipeline by stage of development   biodel inc  monotherapy products in pipeline   biodel inc  pipeline by top  target   biodel inc  pipeline by top  route of administration   biodel inc  pipeline by top  molecule type   biodel inc  pipeline products by top  mechanism of action   highspeed data transmission and high volume needs propel fiber optic connectors market fiber optic connectors are a substantial fragment of the global telecommunication industry optical fibers are joined using fiber optic connectors which allow the light conduction between two consecutive optical fibers an additional im…extensive use of digital technologies for diagnostic applications to boost global optical imaging market the global optical imaging system market is predicted to reach us  billion by  it is expected to grow at a stable rate and will post a cagr of more than  in the coming years the growing market infiltration of digital …foremost trends in global pet care market the global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments it is estimated that the global pet care market will grow at a cagr o…china to review its food security laws china has arisen as the globe’s firmest developing economy in addition china brags about the biggest population pool in the world in recent times the one child policy in the republic was terminated this is anticipated to upsur…improving standards of living to boost global consumer durables market consumer durables is a cataloguing of consumer goods that are not essential to be bought very often as they are fashioned in a way so as to last for an extended period of time profits in the consumer durables sector were most profoundly… united states glycated albumin market report  published jul        price us  onwards        pages  in this report the united states glycated albumin market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report splits the united states market into seven regions  the west  southwest  the middle atlantic  new england  the south  the midwest with sales volume revenue value market share and growth rate of diabetic macular edema  pipeline review h  published jul        price us  onwards        pages  diabetic macular edema  pipeline review h  summary global markets directs latest pharmaceutical and healthcare disease pipeline guide diabetic macular edema  pipeline review h  provides an overview of the diabetic macular edema metabolic disorders pipeline landscape diabetic macular edema dme occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula the part of the eye responsible for detailed  diabetic peripheral neuropathy  pipeline review h  published jul        price us  onwards        pages  diabetic peripheral neuropathy  pipeline review h  summary global markets directs latest pharmaceutical and healthcare disease pipeline guide diabetic peripheral neuropathy  pipeline review h  provides an overview of the diabetic peripheral neuropathy metabolic disorders pipeline landscape diabetic neuropathy is nerve damage caused by diabetes the type of neuropathy occurring in the arms hands legs and feet is known as diabetic pe hypoglycemia  pipeline review h  published jul        price us  onwards        pages  hypoglycemia  pipeline review h  summary global markets directs latest pharmaceutical and healthcare disease pipeline guide hypoglycemia  pipeline review h  provides an overview of the hypoglycemia metabolic disorders pipeline landscape hypoglycemia is a condition characterized by an abnormally low level of blood sugar glucose symptoms of hypoglycemia include tachycardia anxiety shaking and irritability feelings of hunger weak insulin resistance  pipeline review h  published jul        price us  onwards        pages  insulin resistance  pipeline review h  summary global markets directs latest pharmaceutical and healthcare disease pipeline guide insulin resistance  pipeline review h  provides an overview of the insulin resistance metabolic disorders pipeline landscape insulin resistance ir is a condition in which the bodys cells become resistant to the effects of insulin this occurs when insulin levels are sufficiently high over a prolonged per global glycated albumin sales market report  published jul        price us  onwards        pages  in this report the global glycated albumin market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report split global into several key regions with sales k mt revenue million usd market share and growth rate of glycated albumin for these regions from  to  forecast covering  united states  china  europe  japan global neuropathy pain treatment market research report  published jul        price us  onwards        pages  in this report the global neuropathy pain treatment market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report is segmented into several key regions with production consumption revenue million usd market share and growth rate of neuropathy pain treatment in these regions from  to  forecast covering  north america  europe  global north america europe and asiapacific south america middle east and africa glycated albumin market  forecast to  published jul        price us  onwards        pages  diabetes afflicts an increasing number of people worldwide each year proper blood glucose control is essential in preventing complications associated with diabetes such as neuropathy nephropathy and retinopathyscope of the reportthis report focuses on the glycated albumin in global market especially in north america europe and asiapacific south america middle east and africa this report categorizes the market based on manufacturers regions type and application global glycated albumin market research report  published jul        price us  onwards        pages  in this report the global glycated albumin market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report is segmented into several key regions with production consumption revenue million usd market share and growth rate of glycated albumin in these regions from  to  forecast covering  north america  europe  china  j services value for money we believe in optimum utilization of available budget and resources while servicing our clients your market research requirements we keep the same approach in focus to help you get the best value for your s ever growing inventory ranging from the smallest feasible  required data datasheets data facts swot analysis company profiles etc to full research reports that help you make decisions our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than  niche sectors one stop solution need a custom research report on medical devices market require all available business intelligence on d printing industry exploring fb sector of a particular countryregion rnrmarketresearchcom is your onestopsolution to all market intelligence needs we not only offer custom research and consulting services we also bundle reports to meet your needs and help you fetch the data analysis you require for your business dedicated client engagement not limited to only finding relevant reports for you our client engagement team dedicates its efforts to understand your business need and accordingly maps available research data to help you move forward call your client engagement executive any time of your day and get your questions answered in order to make the correct business decision saving time and efforts simply share your research requirement details with us and let us do all the hard work to find required intelligence for you when you add up our one stop solution and dedicated client engagement services mentioned above you obviously know the time and effort saving you do by working with us payment flexibility working with fortune  organizations we understand the importance of being flexible for payments share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done postpurchase research support have questions after reading a report  datasheet bought through us not sure about the methodology used for data available in the research talk to us  share your questions with us and if required we will connect you with the analystsauthors of the reports and ensure you get satisfactory answers for the same need more data  analysis  reports on the topic of your researchproject the rnrmarketresearchcom team is here for you x to support you with your postpurchase requirements subscription offers  packages get in touch with us for more details  salesrnrmarketresearchcom       ad hoc pay  as  you  go  bucket subscriptions fixed cost for of reports customize  personalize as per your needs avail upto  discount on below publisher reports azoth analytics technavio diabetes therapeutics market research reports on market size and competitive analysis advanced search     salesrnrmarketresearchcom search market research reports market research assistance salesrnrmarketresearchcomon the web refine resultby datelast monthlast  monthslast  monthslast yearlast  years by price  home     life sciences    pharmaceuticals    therapeutics    diabetes therapeutics diabetes therapeutics market research reports diabetes therapeutics market research reports titlepublishedprice united states glycated albumin market report by qyresearch group   the west  southwest  the middle atlantic  new england  the south  the midwest with sales volume revenue value market share and growth rate of glycated albumin in these regions from  to jul diabetic macular edema  pipeline review h by global markets direct eline landscape diabetic macular edema dme occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula the part of the eye responsible for detailed central vision common symptoms of dme are blurryjul diabetic peripheral neuropathy  pipeline review h by global markets direct metabolic disorders pipeline landscape diabetic neuropathy is nerve damage caused by diabetes the type of neuropathy occurring in the arms hands legs and feet is known as diabetic peripheral neuropathy symptoms include numbness orjul hypoglycemia  pipeline review h by global markets direct hypoglycemia is a condition characterized by an abnormally low level of blood sugar glucose symptoms of hypoglycemia include tachycardia anxiety shaking and irritability feelings of hunger weakness tiredness dizziness headache confusion jul insulin resistance  pipeline review h by global markets direct ape insulin resistance ir is a condition in which the bodys cells become resistant to the effects of insulin this occurs when insulin levels are sufficiently high over a prolonged period of time causing the bodys own sensitivity tojul global glycated albumin sales market report by qyresearch group enue million usd market share and growth rate of glycated albumin for these regions from  to  forecast covering  united states  china  europe  japan  southeast asia  india jul global neuropathy pain treatment market research report by qyresearch group on consumption revenue million usd market share and growth rate of neuropathy pain treatment in these regions from  to  forecast covering  north america  europe  china  japan  southeast asiajul global north america europe and asiapacific south america middle east and africa glycated albumin market  forecast to by global info research n in global market especially in north america europe and asiapacific south america middle east and africa this report categorizes the market based on manufacturers regions type and applicationmarket segment by manufacturers thisjul global glycated albumin market research report by qyresearch group mption revenue million usd market share and growth rate of glycated albumin in these regions from  to  forecast covering  north america  europe  china  japan  southeast asia  indiajul diabetic foot ulcers  pipeline insight by delve insight oot ulcers this report provides information on the therapeutic development for diabetic foot ulcers dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical preclinical as well as discovery products thjul                 next » avail upto  discount on below publisher reports azoth analytics technavio albireo menu a leader in bile acid biology and the development of novel bile acid modulators albireo is a clinicalstage biopharmaceutical company focused on the development of novel bile acid modulators to address unmet needs in orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders albireo’s clinical pipeline includes a phase  product candidate a phase  product candidate and a third product candidate for which an application for regulatory approval has been submitted in japan albireo’s lead product candidate a is nearing initiation of phase  clinical development in patients with progressive familial intrahepatic cholestasis pfic for more information read albireo’s corporate backgrounder albireo announces closing of  million public offering may   albireo prices  million public offering of common stock may   albireo announces proposed public offering of common stock may   albireo homepage menu this site uses cookies to give you the best possible experience learn more biodel inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report biodel inc  product pipeline review   published by global markets direct product code  published february   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license biodel inc  product pipeline review   published february   content info  pages description summary global markets directs biodel inc  product pipeline review   provides an overview of the biodel incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of biodel incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of biodel inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of biodel incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the biodel incs pipeline products reasons to buy evaluate biodel incs strategic position with total access to detailed information on its product pipeline assess the growth potential of biodel inc in its therapy areas of focus identify new drug targets and therapeutic classes in the biodel incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of biodel inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of biodel inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of biodel inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures biodel inc snapshot biodel inc overview key information key facts biodel inc  research and development overview key therapeutic areas biodel inc  pipeline review pipeline products by stage of development pipeline products  monotherapy biodel inc  pipeline products glance biodel inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities biodel inc  early stage pipeline products preclinical productscombination treatment modalities biodel inc  drug profiles biod product description mechanism of action rd progress biod product description mechanism of action rd progress biod product description mechanism of action rd progress biod product description mechanism of action rd progress biod product description mechanism of action rd progress glucagon product description mechanism of action rd progress viatab product description mechanism of action rd progress biod product description mechanism of action rd progress teriparatide product description mechanism of action rd progress viacal product description mechanism of action rd progress biodel inc  pipeline analysis biodel inc  pipeline products by target biodel inc  pipeline products by route of administration biodel inc  pipeline products by molecule type biodel inc  pipeline products by mechanism of action biodel inc  recent pipeline updates biodel inc  dormant projects biodel inc  discontinued pipeline products discontinued pipeline product profiles biod biod linjeta biodel inc  company statement biodel inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables biodel inc key information biodel inc key facts biodel inc  pipeline by indication  biodel inc  pipeline by stage of development  biodel inc  monotherapy products in pipeline  biodel inc  phase ii  biodel inc  phase i  biodel inc  preclinical  biodel inc  pipeline by target  biodel inc  pipeline by route of administration  biodel inc  pipeline by molecule type  biodel inc  pipeline products by mechanism of action  biodel inc  recent pipeline updates  biodel inc  dormant developmental projects biodel inc  discontinued pipeline products  biodel inc other locations biodel inc subsidiaries list of figures biodel inc  pipeline by top  indication  biodel inc  pipeline by stage of development  biodel inc  monotherapy products in pipeline  biodel inc  pipeline by top  target  biodel inc  pipeline by top  route of administration  biodel inc  pipeline by top  molecule type  biodel inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved biodel inc  wwwinknowvationcom skip to main content welcome guest  register  login  home sbir community sbir awardees tech seekers federal agencies state support services professional service providers sbir stats alphabetized listing of every awardee company registry menudriven search all sbirsttr awards   present techseeker registry® organized by agency organized by state analytics assets techmatching one sbir place about smart office news bureau about us ► companies ► biodel inc biodel inc profile last edited on   saw mill road danbury ct        mediabiodelcom   wwwbiodelcom business identifier treatments for diabetes public profile biodel inc a specialty biopharmaceutical company focuses on the development and commercialization of treatments for diabetes the firms lead product candidate is a glucagon emergency management gem device that is intended to treat diabetes patients experiencing severe hypoglycemia or very low concentrations of blood glucose biodels products are created by utilizing the companys proprietary viadeltm technology which enables rapid delivery of drugs into the blood through various routes of administration faster onset of action and noninvasive routes of delivery improve the efficacy safety compliance and convenience for patients the company is involved in developing proprietary formulations of injectable recombinant human insulin for the treatment of patients with type  and type  diabetes it also develops liquid glucagon formulations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia or very low concentrations of blood glucose the company develops its product candidates by applying its formulation technologies to existing drugs its advanced program involves developing formulations of injectable recombinant human insulin rhi in addition to its ultrarapidacting insulin formulations the company has developed prototype formulations of a liquid glucagon a basal insulin and a glucose responsive insulin in each case for use by patients with diabetes rhibased formulation known as linjeta was the subject of a new drug application nda biodels proprietary drugdelivery technology is applicable to a wide range of peptides proteins and other macromolecules it allows us to alter the pharmacokinetic profile route of administration and stability of drugs that otherwise would be impractical to use as therapeutics because they break down too rapidly biodel is developing novel forms of insulin and other peptide hormones for use in treating diabetes and its complications including hyperglycemia hypoglycemia cardiovascular complications and weight control the company is currently  conducting a phase  clinical trial to assess the pharmacokinetic and pharmacodynamic profiles of biod the reconstituted glucagon formulation intended for use in the gem device it also develops ultrarapidacting proprietary insulin formulations such as biod which has been evaluated in a phase  clinical trial combining recombinant human insulin with its proprietary combination of excipients and biod a concentrated ultrarapidacting insulin formulation  synopsis awardee business condition year founded first sbir year date of last award employee range vc funded ip holdings revenue range privatepublic exchangesymbol   most recent sbir projects year phase agency dollars project title development of novel and stable glucagon formulations for closed loop systems development of concentrated and rapidly absorbed insulins for closed loop systems smart office options sbir firms in the news biodels glucagon formulation for use in a proprietary autoreconstitution device for the trea™ent of severe hypoglycemia meets primary efficacy endpoint in phase  clinical trial biodel successfully defends ultrarapidacting insulin formulation technology in european patent office opposition proceedings biodel announces commercial manufacturing agreement with emergent biosolutions for glucagon rescue product main areas of the site home sbir community sbir stats analytics assets techmatching one sbir place about us contact information innovation development institute llc     beach bluff avenue suite       swampscott  ma    tel      supportinknowvationcom  copyright  innovation development institute llc swampscott ma all rights reserved supportinknowvationcom processing albireo pharma inc nasdaqbiod quotes  news  google financecookies help us deliver our services by using our services you agree to our use of cookieslearn moregot itmy accountsearchmapsyoutubeplaynewsgmaildrivecalendargoogletranslatephotosmoreshoppingwalletfinancedocsbooksbloggercontactshangoutskeepeven more from googlesign inhidden fieldssearch financeadobe flash player is required for interactive charts allowfinancealbireo pharma incnasdaqbiodadd to portfoliocompanysummarynewsrelated companieshistorical pricesfinancialsmarketsnewsportfoliosstock screenergoogle domestic trendsrecent quotes  daysyou have no recent quoteschg   albireo pharma inc  public nasdaqbiod   watch this stock    nov   close nasdaq realtime data  disclaimer currency in usd range       week      open      vol  mkt cap m pe      divyield      eps  shares m beta      inst own  news relevance date all news for albireo pharma inc » subscribe advertisement key stats and ratios q mar   net profit margin   operating margin   ebitd margin   return on average assets   return on average equity   employees   cdp score   screen stocks with similar metrics » address  post office square suite  southboston ma united states  map phone fax website links httpwwwalbireopharmacom external links analyst estimates  marketwatch sec filings  edgar online major holders  msn money research reports  reuters settings  technicals  link to this view volume delayed by  minsprices are not from all markets sources include six advertisement related companies show most recent quarter most recent annual add or remove columns save changes cancel sector healthcare  industry bio therapeutic drugs more from factset » description albireo pharma inc formerly biodel inc is a specialty biopharmaceutical company it is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal gi disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need the target indication for its lead product candidate a is progressive familial intrahepatic cholestasis pfic which is a genetic disorder affecting children a is being evaluated in a phase ii clinical trial other products in the companys pipeline include elobixibat a and bile acid modulators elobixibat is indicated for the treatment of chronic constipation and it has completed its phase iii clinical trials a is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon it has completed a phase ii clinical trial of a prior formulation of a in bile acid malabsorption bam more from reuters » officers and directors david chiswell phd chairman of the board age  bio  compensation   reuters ronald harold wilfred cooper president chief executive officer director age  bio  compensation   reuters thomas a shea chief financial officer treasurer age  bio  compensation   reuters jan mattsson phd chief operating officer age  bio  compensation   reuters peter a zorn esq chief corporate officer general counsel secretary age  bio  compensation   reuters paresh n soni md phd chief medical officer age  bio  compensation   reuters michael gutch phd director bio  compensation   reuters heather preston md director bio  compensation   reuters davey s scoon cpa director age  bio  compensation   reuters denise scotsknight director bio  compensation   reuters full list on reuters » google finance beta available in hong kong  canada  us  china  ukinformation is provided as is and solely for informational purposes not for trading purposes or advice and may be delayedto see all exchange delays please see disclaimer google  google home  blog  help  report a problem  privacy policy  terms of service biodel inc private company information  bloomberg july    am et pharmaceuticals company overview of biodel inc snapshot people company overview as of november   biodel inc was acquired by albireo pharma inc in a reverse merger transaction biodel inc a specialty biopharmaceutical company focuses on the development and commercialization of treatments for diabetes in the united states its lead product candidate is a glucagon emergency management gem device that is intended to treat diabetes patients experiencing severe hypoglycemia or very low concentrations of blood glucose the company completed a phase  clinical trial to assess the pharmacokinetic and pharmacodynamic profiles of biod the reconstituted glucagon formulation intended for use in the gem device it also develops ultrarapidacting proprietary insu as of november   biodel inc was acquired by albireo pharma inc in a reverse merger transaction biodel inc a specialty biopharmaceutical company focuses on the development and commercialization of treatments for diabetes in the united states its lead product candidate is a glucagon emergency management gem device that is intended to treat diabetes patients experiencing severe hypoglycemia or very low concentrations of blood glucose the company completed a phase  clinical trial to assess the pharmacokinetic and pharmacodynamic profiles of biod the reconstituted glucagon formulation intended for use in the gem device it also develops ultrarapidacting proprietary insulin formulations such as biod a concentrated ultrarapidacting insulin formulation in addition the company develops preclinical analogbased ultrarapidacting insulin formulations using insulin lispro the active pharmaceutical ingredient in humalog as well as insulin aspart the active pharmaceutical ingredient in novolog biodel inc was founded in  and is headquartered in danbury connecticut detailed description  saw mill roaddanbury ct united statesfounded in  employees phone  fax  key executives for biodel inc biodel inc does not have any key executives recorded biodel inc key developments biodel inc annual general meeting nov   oct   biodel inc annual general meeting nov   at  us eastern standard time location wiggin and dana llp two stamford plaza  tresser boulevard stamford ct  united states agenda to consider and vote upon a proposal to approve the issuance of shares of biodel common stock to effect a reverse stock split of biodel common stock to approve a new equity incentive plan to elect two class iii directors and to consider and vote upon an adjournment of the annual meeting biodel may sell assets oct   biodel inc nasdaqcmbiod may decide to sell or otherwise liquidate various assets if the pending transaction with albireo ab does not close biodel outlines plan to regain compliance with nasdaq listing requirements sep   biodel inc announced that its  annual meeting of stockholders has been set for october   at that meeting stockholders will vote on among other things matters necessary to complete biodels planned transaction with albireo limited pursuant to a previously announced share exchange agreement including the issuance of shares of biodels common stock in the transaction and a proposed reverse stock split of biodels common stock at a ratio of for shares as expected and as previously announced in a current report on form k filed on september   on september   biodel received a determination letter from the staff of the listing qualifications department of the nasdaq stock market llc or the staff notifying biodel that it had not regained compliance with the  minimum bid price requirement set forth in listing rule a by the previously announced deadline because the date set for biodels  annual meeting of stockholders is after the end of its fiscal year biodel also anticipates the receipt of a second deficiency notice from the staff in early october of this year in connection with the planned share exchange transaction with albireo an initial listing application has been submitted to nasdaq relating to the listing of the common stock of the combined organization following completion of the share exchange in the event biodel has received stockholder approval of the proposals at its  annual meeting of stockholders including the proposal for the issuance of biodels common stock in the transaction and for the proposed reverse stock split and completed the share exchange biodel anticipates that it will be able to demonstrate compliance with all applicable nasdaq listing requirements nasdaqs september   determination letter noted that unless biodel timely requests a hearing before the nasdaq hearings panel or the panel trading of biodels common stock on the nasdaq capital market will be suspended at the opening of business on september   accordingly biodel intends to timely request a hearing before the panel biodels hearing request will automatically stay any action by the staff with respect to the suspension of biodels listing on nasdaq pending the panels decision it is expected that the hearing will be scheduled to occur in november  after the anticipated completion of biodels planned share exchange transaction with albireo biodels plan for addressing the deficiency relating to the timing of its annual meeting will also be scheduled for consideration at the hearing that it will request in the event biodel has demonstrated compliance with all applicable listing requirements prior to the hearing date biodel will request that its hearing before the panel be canceled in the event biodel has not demonstrated compliance with all applicable listing requirements in advance of the hearing date biodel intends to present its plan for achieving compliance to the panel and request a brief extension within which to do so however there can be no assurance that biodel will be successful and that a request to the panel to cancel the hearing or for an extension of time would be granted delisting from the nasdaq capital market would have a material adverse effect on biodels business and on the trading of its common stock similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact biodel inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close biodel inc  product pipeline review   infomarketreportscentercom  us x login sign up facebook twitter linkedin google  mrc blog youtube biodel inc  product pipeline review   home  pharmaceuticals  global markets direct  biodel inc  product pipeline review   report details biodel inc  product pipeline review   sku gmdfeb category pharmaceuticals publisher global markets direct pages  published feb skugmdfeb categorypharmaceuticals publisherglobal markets direct pages published onfeb request discount pay by wireinvoice description table of content list of figures request sample description biodel inc  product pipeline review   summary global markets directs biodel inc  product pipeline review   provides an overview of the biodel incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of biodel incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of biodel inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of biodel incs human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the biodel incs pipeline products reasons to buy  evaluate biodel incs strategic position with total access to detailed information on its product pipeline  assess the growth potential of biodel inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the biodel incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of biodel inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of biodel inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of biodel inc and identify potential opportunities in those areas  avoid intellectual property rights related issues newspress release precision medicine how the life science industry can improve outcomes through to achieve successful precision medicine at scale and to be able to offer it as an everyday treatment option researchers in drug rd need to better understand and manage the reams of unstructured datread more regenerative medicine market to hit  billion by  the current regenerative medicine market is worth  billion globally and will hit over  billion by  as impact of trump administrationread more  benefits of microneedlingmicroneedling hundreds of tiny pin pricks going into your skin might sound weird but it could just be the best thing that ever happened to your faceread more table of content table of contents table of contents  list of tables  list of figures  biodel inc snapshot  biodel inc overview  key information  key facts  biodel inc  research and development overview  key therapeutic areas  biodel inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  biodel inc  pipeline products glance  biodel inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  biodel inc  early stage pipeline products  preclinical productscombination treatment modalities  biodel inc  drug profiles  biod  product description  mechanism of action  rd progress  biod  product description  mechanism of action  rd progress  biod  product description  mechanism of action  rd progress  biod  product description  mechanism of action  rd progress  biod  product description  mechanism of action  rd progress  glucagon  product description  mechanism of action  rd progress  viatab  product description  mechanism of action  rd progress  biod  product description  mechanism of action  rd progress  teriparatide  product description  mechanism of action  rd progress  viacal  product description  mechanism of action  rd progress  biodel inc  pipeline analysis  biodel inc  pipeline products by target  biodel inc  pipeline products by route of administration  biodel inc  pipeline products by molecule type  biodel inc  pipeline products by mechanism of action  biodel inc  recent pipeline updates  biodel inc  dormant projects  biodel inc  discontinued pipeline products  discontinued pipeline product profiles  biod  biod  linjeta  biodel inc  company statement  biodel inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of figures list of tables biodel inc key information  biodel inc key facts  biodel inc  pipeline by indication   biodel inc  pipeline by stage of development   biodel inc  monotherapy products in pipeline   biodel inc  phase ii   biodel inc  phase i   biodel inc  preclinical   biodel inc  pipeline by target   biodel inc  pipeline by route of administration   biodel inc  pipeline by molecule type   biodel inc  pipeline products by mechanism of action   biodel inc  recent pipeline updates   biodel inc  dormant developmental projects  biodel inc  discontinued pipeline products   biodel inc other locations  biodel inc subsidiaries  list of figures biodel inc  pipeline by top  indication   biodel inc  pipeline by stage of development   biodel inc  monotherapy products in pipeline   biodel inc  pipeline by top  target   biodel inc  pipeline by top  route of administration   biodel inc  pipeline by top  molecule type   biodel inc  pipeline products by top  mechanism of action   please select license type single user electronic pdf   site user electronic pdf   enterprise wide electronic pdf   add to cart buy now related reports global electrosurgical products market professional survey report  lighting product markets in the top  american countries to  lighting product markets in the top  asian countries to  lighting product markets in the top  european countries to  global lighting product market to  request sample mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  send request discount mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  send pay by wireinvoice mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  single user electronic pdf site user electronic pdf enterprise wide electronic pdf cd rom hard copy send request quote mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  send market reports center  copyright  all rights reserved   na  nasdaqbiod  stock quote  news  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street na biod follow  nasdaq prev close  day lowhigh     wk lowhigh    exchange nasdaq div  yield na na trade with jim cramer  days free latest news  biotech stocks under  to trade for big gains  stocks under  set to soar mustsee charts  stocks under  making big moves higher when a stock makes a largepercentage move it is often just the start of a new major trend  a trend that can lead to huge profits sep    pm edt  breakout biotech stocks trading for under  keep these biotech stocks trading for under  on your breakout trading radar sep    pm edt ratings changes today thestreet quant ratings provides fair and objective information to help you make educated investing decisions we rate over  stocks daily and provide page pdf reports for each stock these ratings can change daily and todays changes are reflected in the email below if you are looking to checkup on the stocks you currently own or are looking for new ideas you can find our full database of passwordprotected ratings reports in our proprietary ratings screener httpwwwthestreetcomkqrflatstockscreenerhtml upgrades aan axti downgrades asb cvrr ej iknx nvfy initiations biod read on to get thestreet quant ratings detailed report dec    am est  stocks under  set to soar these under stocks look ready to break out and trade higher from current levels jul    pm edt biodel reports second quarter fiscal year  financial results conference call and audio webcast will be held today may th at  pm et may    pm edt biodel to report second quarter fiscal year  financial results on may   may    pm edt biodel announces collaboration agreement with hec pharm for development of ultrarapidacting insulin aspart formulation apr    pm edt biodel announces commercial manufacturing agreement with emergent biosolutions for glucagon rescue product mar    pm est biodel to present at the th annual roth conference mar    am est  biotech stocks to trade for breakouts heres a technical look at five potentially explosive biotech stock plays feb    pm est biodel announces plans to advance biod based on positive clinical trial results feb    pm est biodel reports first quarter fiscal year  financial results conference call and audio webcast will be held today february th at  pm et feb    pm est biodel to report first quarter fiscal year  financial results on february   feb    pm est biodel to present at upcoming conferences feb    pm est  stocks under  set to soar these under stocks look ready to trade higher from current levels jan    pm est first week of biod february nd options trading investors in biodel inc saw new options begin trading this week for the february nd expiration at stock options channel our yieldboost formula has looked up and down the biod options chain for the new february nd contracts and identified one put and one call contract of particular interest jan    am est biodel offers opportunity in the growing insulin glucagon markets as the diabetes insulin market continues to heat up biodel offers significant upside with its new offerings dec    am est biodel reports fourth quarter fiscal year  financial results conference call and audio webcast will be held today december th at  pm et dec    pm est biodel announces commercial supply agreement with bd for liquid glucagon rescue device dec    am est biodel to report fourth quarter fiscal year  financial results on december   dec    am est biodel advances ultrarapidacting concentrated insulin formulation into clinical development top line data expected in first quarter of  nov    pm est interesting biod put and call for november th investors in biodel inc saw new options become available this week for the november th expiration at stock options channel our yieldboost formula has looked up and down the biod options chain for the new november th contracts and identified one put and one call contract of particular interest oct    am edt january  options now available for biodel biod investors in biodel inc saw new options become available today for the january  expiration one of the key data points that goes into the price an option buyer is willing to pay is the time value so with  days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration sep    am edt biodel fails to excite investors with metoo mealtime insulin but if biodel shares are still too cheap mannkind is too expensive sep    am edt biodels biod achieves primary endpoint in phase  clinical trial demonstrating glycemic control comparable to humalogr conference call and webcast will be held monday september th at  am edt sep    pm edt  stocks ready to break out these stocks look poised to break out and trade higher from current levels aug    pm edt biotechs next big thing fall trials its been a busy summer for biotech but the coming weeks will heat up with trials from biodel achillon and coronado says adam feuerstein sr columnist at thestreet aug    am edt first week of october th options trading for biodel biod investors in biodel inc saw new options begin trading this week for the october th expiration at stock options channel our yieldboost formula has looked up and down the biod options chain for the new october th contracts and identified one put and one call contract of particular interest aug    pm edt next load more from our partners exploring grahams netnet working capital strategy part  the first  months seekingalpha biodel reports fq results seekingalpha biodel downgraded to neutral from buy at ladenburg the fly biodel downgraded to market perform from outperform at william blair the fly new strong buy stocks for october th zacks biodel initiated with a buy at roth capital the fly biodel initiated with a buy at roth capital the fly valeant up on betterthanexpected  outlook eyes deals  analyst blog zacks infinity pharmaceuticals falls on duvelisib study results  analyst blog zacks ptc therapeutics starts rolling nda filing for translarna  analyst blog zacks widerthanexpected loss at biodel  analyst blog zacks afternoon market losers benzinga wedbush securities reiterates neutral rating  pt on biodel benzinga zacks  rank additions for tuesday  tale of the tape zacks zacks  rank additions for monday  tale of the tape zacks trending walmart in focus amid horrific human trafficking incident in texas that causes nine deaths trump just resurrected the ugly practice known as civil forfeiture for no reason  things you must know before the market opens monday ftc seen as set to block rite aid deal billionaire mark cuban the rise of technology will cause a lot of unemployment advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers